drugset / Trial / NCT03708848

Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

NCT03708848

Phase 4 Completed 112 enrolled Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

Increasing drug resistance presents a significant challenge to the efficacies of common empiric eradication regimens for Helicobacter pylori treatment in the mainland of China. Tailored therapy may be the best choice to achieve good efficacy, especially in patients with penicillin allergy. Few studies had evaluated the patients with penicillin allergy.This study is designed to evaluate the efficacy and safety of antibiotic sensitivity-based tailored therapy for Helicobacter pylori treatment in the patients with penicillin allergy.

Timeline

Start
2018-12-05
Primary completion
2019-09-30
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bismuth Potassium Citrate Unknown 600 mg
Subject Clarithromycin Small molecule 0.5 g
Subject Esomeprazole Small molecule 20 mg
Subject Levofloxacin Small molecule 0.5 g
Subject Metronidazole Small molecule 0.4 g
Subject Tetracycline Unknown 0.4 g